CN109507127A - It is a kind of for detecting the kit of LBP content in human blood - Google Patents
It is a kind of for detecting the kit of LBP content in human blood Download PDFInfo
- Publication number
- CN109507127A CN109507127A CN201811497826.8A CN201811497826A CN109507127A CN 109507127 A CN109507127 A CN 109507127A CN 201811497826 A CN201811497826 A CN 201811497826A CN 109507127 A CN109507127 A CN 109507127A
- Authority
- CN
- China
- Prior art keywords
- lbp
- buffer
- kit
- reagent
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 20
- 239000008280 blood Substances 0.000 title claims abstract description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000000872 buffer Substances 0.000 claims abstract description 38
- 239000004471 Glycine Substances 0.000 claims abstract description 23
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 17
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 17
- 239000004793 Polystyrene Substances 0.000 claims abstract description 15
- 229920002223 polystyrene Polymers 0.000 claims abstract description 15
- 239000003381 stabilizer Substances 0.000 claims abstract description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004816 latex Substances 0.000 claims abstract description 11
- 229920000126 latex Polymers 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 239000000725 suspension Substances 0.000 claims abstract description 7
- 239000004005 microsphere Substances 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims abstract description 6
- 230000002335 preservative effect Effects 0.000 claims abstract description 6
- 238000000746 purification Methods 0.000 claims abstract description 5
- 239000003223 protective agent Substances 0.000 claims abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 238000002835 absorbance Methods 0.000 claims description 18
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 229940037003 alum Drugs 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 9
- 229960000281 trometamol Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 claims description 8
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- -1 alum Chemical compound 0.000 claims description 7
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical group [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 230000009849 deactivation Effects 0.000 claims description 6
- 239000001177 diphosphate Substances 0.000 claims description 6
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 6
- 235000011180 diphosphates Nutrition 0.000 claims description 6
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 238000010998 test method Methods 0.000 claims description 4
- 238000010146 3D printing Methods 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 206010018910 Haemolysis Diseases 0.000 claims description 3
- 239000007832 Na2SO4 Substances 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 239000000956 alloy Substances 0.000 claims description 3
- 229910045601 alloy Inorganic materials 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000006177 biological buffer Substances 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 238000011088 calibration curve Methods 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 230000005685 electric field effect Effects 0.000 claims description 3
- 125000003700 epoxy group Chemical group 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000011010 flushing procedure Methods 0.000 claims description 3
- 125000000524 functional group Chemical group 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims description 3
- 230000008588 hemolysis Effects 0.000 claims description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 3
- 229940033663 thimerosal Drugs 0.000 claims description 3
- 102100035131 Lipopolysaccharide-binding protein Human genes 0.000 claims 12
- ZXPSRPAUXQIYID-UHFFFAOYSA-N [N].[Na] Chemical compound [N].[Na] ZXPSRPAUXQIYID-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000007616 round robin method Methods 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000002699 waste material Substances 0.000 abstract description 2
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920006389 polyphenyl polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N2021/3125—Measuring the absorption by excited molecules
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention belongs to kit technical fields; disclose a kind of for detecting the kit of LBP content in human blood, the kit for detecting LBP content in human blood includes: stabilizer, preservative, suspension stabilizer, buffer, EDTA, increases solidifying agent, protective agent, the polystyrene latex microspheres for being crosslinked LBP antibody.The preparation method of buffer glycine provided by the invention, has efficient, energy saving, no three wastes, saves material, and improves the advantages such as product quality, improves soda acid buffering effect；Meanwhile beta glucan being provided and prepares purification process, the molecular structure and chemical quality of beta glucan will not be not only destroyed, the purity and yield of beta glucan can be also effectively promoted, improve the testing result of kit.
Description
Technical field
The invention belongs to kit technical fields more particularly to a kind of for detecting the reagent of LBP content in human blood
Box.
Background technique
Lipopolysaccharides (LPS) binding protein (LBP) is to be present in one of normal person and animal blood serum glycoprotein, human serum
The normal concentration of middle LBP is 5~10 μ g/ml, and Acute response stage can be increased to 200 μ g/ml.Lipoid A in LBP and LPS has
High affinity can be used as LPS carrier protein, be catalyzed LPS in conjunction with CD14, and stimulation monocyte, endothelial cell etc. promote
The release of the inflammatory mediators such as TNF；LBP is alternatively arranged as opsonin, the LPS and Grain-negative after promoting the phagocytosiss such as monocyte conditioning
Bacterium, therefore inflammatory reaction caused by the adjustable LPS of LBP.BPI is the biological antagonist of LBP, has chemistry similar with LPB
Structure also has high affinity with LPS, can be competitively in conjunction with LPS, the LPS inflammatory reaction of antagonism LBP mediation.
However, being currently used for detecting in human blood, buffer glycine used in the kit of LBP content is of low quality, influences soda acid
Buffering effect；Meanwhile the low influence testing result of reagent glucan purity.
In conclusion problem of the existing technology is: being currently used for the kit institute of LBP content in detection human blood
Buffer glycine is of low quality, influences soda acid buffering effect；Meanwhile the low influence testing result of reagent glucan purity.
Summary of the invention
In view of the problems of the existing technology, the present invention provides a kind of for detecting the examination of LBP content in human blood
Agent box.
The invention is realized in this way a kind of kit for detecting LBP content in human blood includes:
Stabilizer, suspension stabilizer, buffer, EDTA, increases solidifying agent, protective agent, the polyphenyl for being crosslinked LBP antibody at preservative
Ethylene latex microballoon；
Stabilizer is selected from KCl, NaCl, CaCl2、Na2CO3、Na2SO4Or K2SO4One or more combinations；
Preservative is Sodium azide, thimerosal or ProClin300；
Suspension stabilizer is PEG8000, sucrose, glycerol or glucose；
Buffer includes: threose, alum, Fructose Diphosphate, calgon and glycine, and stachyose, alum, fruit
Sugared diphosphate sodium, calgon, glycine total concentration be 4-7.5g/L, the pH value of biological buffer 1 is 7.4-7.6；
The concentration of EDTA is 20~100mmol/L；
Increasing solidifying agent is PEG8000 or beta glucan；
The surface functional group of polystyrene latex microballoon is amino, carboxyl, hydrazides, aldehyde radical or epoxy group, polystyrene cream
The partial size of glue microballoon is in 200~600nm；
A kind of kit test method for detecting LBP content in human blood is as follows:
Step 1, reagent prepare；
(1) preparation of reagent A:
Configure buffer: glycine 1.9g/L, stachyose 2g/L, alum 0.5g/L, Fructose Diphosphate 2g/L, six inclined phosphorus
Sour sodium 0.4g/L, solvent are water, PH7.4.
Bovine serum albumin(BSA) 2.0g/L, disodium ethylene diamine tetraacetate 4.0g/L, PEG80002.8g/ are added in buffer
L, Sodium azide 1.8g/L, sodium chloride 2.0g/L, are uniformly mixed to get reagent A；
(2) preparation of reagent B:
LBP antibody is subjected to 4 DEG C of dialysis, then LBP antibody is diluted to 2mg/ml with buffer 2, obtains the dilution of LBP antibody
Liquid；Polystyrene latex microspheres distilled water is centrifuged, washing 3 times；
With buffer 2 (tromethamine buffer 75mmol/L, PH7.2) by by upper step washing after polystyrene colloidal
It is 1% that newborn microballoon, which is diluted to mass concentration, adds the EDC that mass concentration is 0.02%-0.1%, reaction is stirred at room temperature
30min, after reaction then it is dilute that the LBP antibody walked is added to remove unreacted EDC in 15000rpm centrifuge washing
Liquid is released, is stirred to react 30min at room temperature, terminate liquid is added and terminates reaction, obtained reaction solution 15000rpm is centrifuged, with slow
Fliud flushing 2 (tromethamine buffer 75mmol/L, PH7.2) washing precipitating, repeated centrifugation are washed 3 times, and buffer 2 is eventually adding
(tromethamine buffer 75mmol/L, PH7.2), PEG80002.8g/L, Sodium azide 1.8g/L, bovine serum albumin(BSA) is added
2.0g/L, disodium ethylene diamine tetraacetate 4.0g/L, sodium chloride 2.0g/L are uniformly mixed up to reagent B.
(3) lipopolysaccharide binding protein reference calibrations product concentration as required is by corresponding lipopolysaccharide binding protein standard items
It is separately added into above-mentioned buffer, one group of calibration object of various concentration is prepared.
Step 2, full automatic biochemical apparatus parameter setting；
(a) Detection wavelength: dominant wavelength 600nm, a length of none of complementary wave；
(b) detection temperature: 37 DEG C；
(c) reaction time: 10min, wherein the absorbance M of measurement reading immediately is added after reagent B in incubation time 5min1, 5
Absorbance M is read after minute2, calculate absorbance change Δ M=M2-M1；
(d) the Direction of Reaction: negative direction
Step 3, detection operation；
(a) 200ul reagent A and 5ul serum sample (avoiding haemolysis) is taken to mix；
(b) by the solution after mixing in 37 DEG C of incubation time 5min；
(c) 50ul reagent B is added, absorbance M is read in measurement immediately1, absorbance M is read after five minutes2, calculate absorbance
Changes delta M=M2-M1。
Step 4 calculates the content of lipopolysaccharide binding protein LBP in sample by calibration curve；
Further, the glycine the preparation method is as follows:
(1) monoxone, catalyst and multicomponent solvent are added in reactor using halo acid system, are passed through liquefied ammonia and are followed
Glycine and ammonium chloride mixed liquor, catalyst circulation reuse can be obtained in around-France synthetic reaction；
(2) mixed liquor enters in ion membrane separation device, under DC electric field effect, controls isoelectric point pH value and electric current is close
Degree, NH4 +And Cl-It is migrated away respectively, forms NH4Cl solution, transport NH in mixed liquor4After Cl, most of sweet ammonia is left
Acid；
(3) residual mixed liquor is precipitated by crystallization up to product glycine.
Further, the isolation and purification method of the beta glucan is as follows:
(1) crops are crushed, adds water, in 60~90 DEG C of stirring and dissolvings, filtering is extracted initial molten containing beta glucan
Liquid；
(2) initial soln is filtered with the sieve that aperture is 0.3~0.6mm, collects filtrate, obtains separating liquid；
(3) organic solution of isopropanol and petroleum ether mixing is added into separating liquid, 35~40min of degreasing is added
80%~90% ethyl alcohol, adjusting separating liquid pH value is 9~10, in 85~90 DEG C, 5~6h of enzyme deactivation；Wherein, organic solution with separate
The volume ratio of liquid is 1:10~1:15, and the volume ratio of ethyl alcohol and separating liquid is 1:15~1:20, isopropanol and stone in organic solution
The volume ratio of oily ether is 1~3:2~5；
(4) by 3D printing technique, Co-based alloy powder is used aperture to be prepared as 0.2~0.3 μm of metal filtration film,
Solution under conditions of 0.3~0.4MPa, after filtering the enzyme deactivation that the step (3) obtains；
(5) under 0.5~1.0MPa, in the filter press of several connections, the filter that aperture is 0.09~0.1 μm is respectively adopted
Cloth filters pressing step (4) 0.5~2h of acquired solution to get the various concentration after isolating and purifying beta glucan solution.
Advantages of the present invention and good effect are as follows: the preparation method of buffer glycine provided by the invention, have efficiently,
Energy conservation, no three wastes, save material, and improve the advantages such as product quality, improve soda acid buffering effect；Meanwhile providing beta glucan
Purification process is prepared, the molecular structure and chemical quality of beta glucan will not be not only destroyed, can also effectively promote beta glucan
Purity and yield improve the testing result of kit.
Detailed description of the invention
Fig. 1 is provided in an embodiment of the present invention for detecting the reagent cartridge configuration block diagram of LBP content in human blood.
Fig. 2 is provided in an embodiment of the present invention for detecting the kit test method process of LBP content in human blood
Figure.
Specific embodiment
In order to further understand the content, features and effects of the present invention, the following examples are hereby given, and cooperate attached drawing
Detailed description are as follows.
Structure of the invention is explained in detail with reference to the accompanying drawing.
As shown in Figure 1, the kit provided by the present invention for LBP content in detection human blood includes: stabilizer, prevents
Rotten agent, buffer, EDTA, increases solidifying agent, protective agent, the polystyrene latex microspheres for being crosslinked LBP antibody at suspension stabilizer；
Stabilizer is selected from KCl, NaCl, CaCl2、Na2CO3、Na2SO4Or K2SO4One or more combinations；
Preservative is Sodium azide, thimerosal or ProClin300；
Suspension stabilizer is PEG8000, sucrose, glycerol or glucose；
Buffer includes: threose, alum, Fructose Diphosphate, calgon and glycine, and stachyose, alum, fruit
Sugared diphosphate sodium, calgon, glycine total concentration be 4-7.5g/L, the pH value of biological buffer 1 is 7.4-7.6；
The concentration of EDTA is 20~100mmol/L；
Increasing solidifying agent is PEG8000 or beta glucan；
The surface functional group of polystyrene latex microballoon is amino, carboxyl, hydrazides, aldehyde radical or epoxy group, polystyrene cream
The partial size of glue microballoon is in 200~600nm；
As shown in Fig. 2, a kind of kit test method for detecting LBP content in human blood is as follows:
Step S101, reagent prepare；
(1) preparation of reagent A:
Configure buffer: glycine 1.9g/L, stachyose 2g/L, alum 0.5g/L, Fructose Diphosphate 2g/L, six inclined phosphorus
Sour sodium 0.4g/L, solvent are water, PH7.4.
Bovine serum albumin(BSA) 2.0g/L, disodium ethylene diamine tetraacetate 4.0g/L, PEG80002.8g/ are added in buffer
L, Sodium azide 1.8g/L, sodium chloride 2.0g/L, are uniformly mixed to get reagent A；
(2) preparation of reagent B:
LBP antibody is subjected to 4 DEG C of dialysis, then LBP antibody is diluted to 2mg/ml with buffer 2, obtains the dilution of LBP antibody
Liquid；Polystyrene latex microspheres distilled water is centrifuged, washing 3 times；
With buffer 2 (tromethamine buffer 75mmol/L, PH7.2) by by upper step washing after polystyrene colloidal
It is 1% that newborn microballoon, which is diluted to mass concentration, adds the EDC that mass concentration is 0.02%-0.1%, reaction is stirred at room temperature
30min, after reaction then it is dilute that the LBP antibody walked is added to remove unreacted EDC in 15000rpm centrifuge washing
Liquid is released, is stirred to react 30min at room temperature, terminate liquid is added and terminates reaction, obtained reaction solution 15000rpm is centrifuged, with slow
Fliud flushing 2 (tromethamine buffer 75mmol/L, PH7.2) washing precipitating, repeated centrifugation are washed 3 times, and buffer 2 is eventually adding
(tromethamine buffer 75mmol/L, PH7.2), PEG80002.8g/L, Sodium azide 1.8g/L, bovine serum albumin(BSA) is added
2.0g/L, disodium ethylene diamine tetraacetate 4.0g/L, sodium chloride 2.0g/L are uniformly mixed up to reagent B.
(3) lipopolysaccharide binding protein reference calibrations product concentration as required is by corresponding lipopolysaccharide binding protein standard items
It is separately added into above-mentioned buffer, one group of calibration object of various concentration is prepared.
Step S102, full automatic biochemical apparatus parameter setting；
(a) Detection wavelength: dominant wavelength 600nm, a length of none of complementary wave；
(b) detection temperature: 37 DEG C；
(c) reaction time: 10min, wherein the absorbance M of measurement reading immediately is added after reagent B in incubation time 5min1, 5
Absorbance M is read after minute2, calculate absorbance change Δ M=M2-M1；
(d) the Direction of Reaction: negative direction
Step S103, detection operation；
(a) 200ul reagent A and 5ul serum sample (avoiding haemolysis) is taken to mix；
(b) by the solution after mixing in 37 DEG C of incubation time 5min；
(c) 50ul reagent B is added, absorbance M is read in measurement immediately1, absorbance M is read after five minutes2, calculate absorbance
Changes delta M=M2-M1。
Step S104 calculates the content of lipopolysaccharide binding protein LBP in sample by calibration curve；
Glycine provided by the invention the preparation method is as follows:
(1) monoxone, catalyst and multicomponent solvent are added in reactor using halo acid system, are passed through liquefied ammonia and are followed
Glycine and ammonium chloride mixed liquor, catalyst circulation reuse can be obtained in around-France synthetic reaction；
(2) mixed liquor enters in ion membrane separation device, under DC electric field effect, controls isoelectric point pH value and electric current is close
Degree, NH4 +And Cl-It is migrated away respectively, forms NH4Cl solution, transport NH in mixed liquor4After Cl, most of sweet ammonia is left
Acid；
(3) residual mixed liquor is precipitated by crystallization up to product glycine.
The isolation and purification method of beta glucan provided by the invention is as follows:
(1) crops are crushed, adds water, in 60~90 DEG C of stirring and dissolvings, filtering is extracted initial molten containing beta glucan
Liquid；
(2) initial soln is filtered with the sieve that aperture is 0.3~0.6mm, collects filtrate, obtains separating liquid；
(3) organic solution of isopropanol and petroleum ether mixing is added into separating liquid, 35~40min of degreasing is added
80%~90% ethyl alcohol, adjusting separating liquid pH value is 9~10, in 85~90 DEG C, 5~6h of enzyme deactivation；Wherein, organic solution with separate
The volume ratio of liquid is 1:10~1:15, and the volume ratio of ethyl alcohol and separating liquid is 1:15~1:20, isopropanol and stone in organic solution
The volume ratio of oily ether is 1~3:2~5；
(4) by 3D printing technique, Co-based alloy powder is used aperture to be prepared as 0.2~0.3 μm of metal filtration film,
Solution under conditions of 0.3~0.4MPa, after filtering the enzyme deactivation that the step (3) obtains；
(5) under 0.5~1.0MPa, in the filter press of several connections, the filter that aperture is 0.09~0.1 μm is respectively adopted
Cloth filters pressing step (4) 0.5~2h of acquired solution to get the various concentration after isolating and purifying beta glucan solution.
The above is only the preferred embodiments of the present invention, and is not intended to limit the present invention in any form,
Any simple modification made to the above embodiment according to the technical essence of the invention, equivalent variations and modification, belong to
In the range of technical solution of the present invention.
Claims (4)
1. a kind of for detecting the kit of LBP content in human blood, which is characterized in that described for detecting in human blood
The kit of LBP content includes:
Stabilizer, suspension stabilizer, buffer, EDTA, increases solidifying agent, protective agent, the polystyrene for being crosslinked LBP antibody at preservative
Latex microsphere；
Stabilizer is selected from KCl, NaCl, CaCl2、Na2CO3、Na2SO4Or K2SO4One or more combinations；
Preservative is Sodium azide, thimerosal or ProClin300；
Suspension stabilizer is PEG8000, sucrose, glycerol or glucose；
Buffer includes: threose, alum, Fructose Diphosphate, calgon and glycine, and stachyose, alum, fructose two
Sodium phosphate, calgon, glycine total concentration be 4-7.5g/L, the pH value of biological buffer 1 is 7.4-7.6；
The concentration of EDTA is 20~100mmol/L；
Increasing solidifying agent is PEG8000 or beta glucan；
The surface functional group of polystyrene latex microballoon is amino, carboxyl, hydrazides, aldehyde radical or epoxy group, and polystyrene latex is micro-
The partial size of ball is in 200~600nm.
2. as described in claim 1 for detecting the kit of LBP content in human blood, which is characterized in that described for examining
The kit test method for surveying LBP content in human blood is as follows:
Step 1, reagent prepare；
(1) preparation of reagent A:
Configure buffer: glycine 1.9g/L, stachyose 2g/L, alum 0.5g/L, Fructose Diphosphate 2g/L, calgon
0.4g/L, solvent are water, PH7.4.
Bovine serum albumin(BSA) 2.0g/L is added in buffer, disodium ethylene diamine tetraacetate 4.0g/L, PEG80002.8g/L, folds
Nitrogen sodium 1.8g/L, sodium chloride 2.0g/L, are uniformly mixed to get reagent A；
(2) preparation of reagent B:
LBP antibody is subjected to 4 DEG C of dialysis, then LBP antibody is diluted to 2mg/ml with buffer 2, obtains LBP antibody diluent；
Polystyrene latex microspheres distilled water is centrifuged, washing 3 times；
It is with buffer 2 (tromethamine buffer 75mmol/L, PH7.2) that the polystyrene latex after the washing of upper step is micro-
It is 1% that ball, which is diluted to mass concentration, adds the EDC that mass concentration is 0.02%-0.1%, reaction is stirred at room temperature
30min, after reaction then it is dilute that the LBP antibody walked is added to remove unreacted EDC in 15000rpm centrifuge washing
Liquid is released, is stirred to react 30min at room temperature, terminate liquid is added and terminates reaction, obtained reaction solution 15000rpm is centrifuged, with slow
Fliud flushing 2 (tromethamine buffer 75mmol/L, PH7.2) washing precipitating, repeated centrifugation are washed 3 times, and buffer 2 is eventually adding
(tromethamine buffer 75mmol/L, PH7.2), PEG80002.8g/L, Sodium azide 1.8g/L, bovine serum albumin(BSA) is added
2.0g/L, disodium ethylene diamine tetraacetate 4.0g/L, sodium chloride 2.0g/L are uniformly mixed up to reagent B.
(3) lipopolysaccharide binding protein reference calibrations product concentration as required distinguishes corresponding lipopolysaccharide binding protein standard items
Above-mentioned buffer is added, one group of calibration object of various concentration is prepared.
Step 2, full automatic biochemical apparatus parameter setting；
(a) Detection wavelength: dominant wavelength 600nm, a length of none of complementary wave；
(b) detection temperature: 37 DEG C；
(c) reaction time: 10min, wherein the absorbance M of measurement reading immediately is added after reagent B in incubation time 5min1, 5 minutes
Absorbance M is read afterwards2, calculate absorbance change Δ M=M2-M1；
(d) the Direction of Reaction: negative direction
Step 3, detection operation；
(a) 200ul reagent A and 5ul serum sample (avoiding haemolysis) is taken to mix；
(b) by the solution after mixing in 37 DEG C of incubation time 5min；
(c) 50ul reagent B is added, absorbance M is read in measurement immediately1, absorbance M is read after five minutes2, calculate absorbance change
Δ M=M2-M1。
Step 4 calculates the content of lipopolysaccharide binding protein LBP in sample by calibration curve；
3. as described in claim 1 for detecting the kit of LBP content in human blood, which is characterized in that the glycine
The preparation method is as follows:
(1) monoxone, catalyst and multicomponent solvent are added in reactor using halo acid system, are passed through liquefied ammonia and carry out round-robin method
Glycine and ammonium chloride mixed liquor, catalyst circulation reuse can be obtained in synthetic reaction；
(2) mixed liquor enters in ion membrane separation device, under DC electric field effect, controls isoelectric point pH value and current density,
NH4 +And Cl-It is migrated away respectively, forms NH4Cl solution, transport NH in mixed liquor4After Cl, most of glycine is left；
(3) residual mixed liquor is precipitated by crystallization up to product glycine.
4. as described in claim 1 for detecting the kit of LBP content in human blood, which is characterized in that the β-Portugal is poly-
The isolation and purification method of sugar is as follows:
(1) crops are crushed, adds water, in 60~90 DEG C of stirring and dissolvings, the initial soln containing beta glucan is extracted in filtering；
(2) initial soln is filtered with the sieve that aperture is 0.3~0.6mm, collects filtrate, obtains separating liquid；
(3) it is added the organic solution of isopropanol and petroleum ether mixing into separating liquid, 35~40min of degreasing, add 80%~
90% ethyl alcohol, adjusting separating liquid pH value is 9~10, in 85~90 DEG C, 5~6h of enzyme deactivation；Wherein, the body of organic solution and separating liquid
For product than being 1:10~1:15, the volume ratio of ethyl alcohol and separating liquid is 1:15~1:20, isopropanol and petroleum ether in organic solution
Volume ratio is 1~3:2~5；
(4) by 3D printing technique, Co-based alloy powder is used aperture to be prepared as 0.2~0.3 μm of metal filtration film, in
Solution under conditions of 0.3~0.4MPa, after filtering the enzyme deactivation that the step (3) obtains；
(5) under 0.5~1.0MPa, in the filter press of several connections, the filter cloth pressure that aperture is 0.09~0.1 μm is respectively adopted
Filter step (4) 0.5~2h of acquired solution to get the various concentration after isolating and purifying beta glucan solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811497826.8A CN109507127A (en) | 2018-12-07 | 2018-12-07 | It is a kind of for detecting the kit of LBP content in human blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811497826.8A CN109507127A (en) | 2018-12-07 | 2018-12-07 | It is a kind of for detecting the kit of LBP content in human blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109507127A true CN109507127A (en) | 2019-03-22 |
Family
ID=65753040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811497826.8A Pending CN109507127A (en) | 2018-12-07 | 2018-12-07 | It is a kind of for detecting the kit of LBP content in human blood |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109507127A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112649598A (en) * | 2020-12-29 | 2021-04-13 | 上海云泽生物科技有限公司 | Latex-enhanced immunoturbidimetry kit for determining vancomycin |
| CN116270522A (en) * | 2023-04-27 | 2023-06-23 | 北京华靳制药有限公司 | Fructose diphosphate sodium capsule and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1139485A (en) * | 1994-01-24 | 1997-01-01 | 爱克斯欧玛公司 | Method for quantifying LBP in body fluids |
| CN104262183A (en) * | 2014-08-26 | 2015-01-07 | 陕西盛迈石油有限公司 | Preparation method of glycine |
| CN104407156A (en) * | 2014-12-05 | 2015-03-11 | 重庆中元生物技术有限公司 | Latex enhanced immunoturbidimetry kit for detecting lipopolysaccharide binding protein (LBP) |
| CN106699583A (en) * | 2015-11-16 | 2017-05-24 | 青岛森美克化工技术有限公司 | Preparation method of glycine |
| CN107082825A (en) * | 2017-06-01 | 2017-08-22 | 四川惠泰农业科技有限公司 | The isolation and purification method of beta glucan |
-
2018
- 2018-12-07 CN CN201811497826.8A patent/CN109507127A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1139485A (en) * | 1994-01-24 | 1997-01-01 | 爱克斯欧玛公司 | Method for quantifying LBP in body fluids |
| CN104262183A (en) * | 2014-08-26 | 2015-01-07 | 陕西盛迈石油有限公司 | Preparation method of glycine |
| CN104407156A (en) * | 2014-12-05 | 2015-03-11 | 重庆中元生物技术有限公司 | Latex enhanced immunoturbidimetry kit for detecting lipopolysaccharide binding protein (LBP) |
| CN106699583A (en) * | 2015-11-16 | 2017-05-24 | 青岛森美克化工技术有限公司 | Preparation method of glycine |
| CN107082825A (en) * | 2017-06-01 | 2017-08-22 | 四川惠泰农业科技有限公司 | The isolation and purification method of beta glucan |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112649598A (en) * | 2020-12-29 | 2021-04-13 | 上海云泽生物科技有限公司 | Latex-enhanced immunoturbidimetry kit for determining vancomycin |
| CN116270522A (en) * | 2023-04-27 | 2023-06-23 | 北京华靳制药有限公司 | Fructose diphosphate sodium capsule and preparation method thereof |
| CN116270522B (en) * | 2023-04-27 | 2024-04-19 | 北京华靳制药有限公司 | Fructose diphosphate sodium capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106124282B (en) | A kind of method of lamination centrifugal filtration separation and Extraction excretion body | |
| CN107532195B (en) | Method for separating extracellular vesicles by using aqueous two-phase system | |
| Kunitz | Crystalline ribonuclease | |
| CN110003323A (en) | A kind of method that double-aqueous phase system isolates and purifies protein | |
| EP3246703A1 (en) | Method and kit for capturing extracellular vesicles (evs) on a solid surface | |
| CN105017412B (en) | A method of the separating high-purity bovine serum albumin(BSA) from cow's serum | |
| US8501430B2 (en) | Determination of biological material ingredients | |
| EP2479268A1 (en) | Dissociation method and dissociation agent for avidin and biotin | |
| CN109507127A (en) | It is a kind of for detecting the kit of LBP content in human blood | |
| CN109576207A (en) | A kind of separation method of the extracellular vesica based on metal ion network mixture | |
| CN109251886B (en) | Kit for extracting adipose tissue-derived exosomes and extraction method and application thereof | |
| CN108299552A (en) | The extracting method of goat dairy milk fat globule membrane protein for proteomics research | |
| CN110411816A (en) | A kind of enrichment method of excretion body | |
| CN109342743B (en) | Preparation method of denatured IgG capable of being efficiently combined with rheumatoid factor | |
| CN105153440B (en) | A kind of preparation method of dextran microspheres gel | |
| US10859555B2 (en) | Methods of isolating and detecting metal ions from proteins | |
| EP1386160B1 (en) | Method for detecting blood cell antigens and the antibodies in response to the same | |
| CN114164203B (en) | Extracellular vesicle purification material and purification method | |
| CN205898536U (en) | Separation and extraction secretes stromatolite centrifugal filtration device of body outward | |
| CN112980006A (en) | Protein cross-linked nano affinity microsphere, preparation method and application | |
| CN108548921A (en) | A kind of indirect antihuman globulin accelerates the test method of match | |
| CN111141913A (en) | Ceruloplasmin detection kit and preparation method thereof | |
| JPH0136066B2 (en) | ||
| CN105693922A (en) | Amphiprotic protein ice gel imprinted polymer, and preparation method and application thereof | |
| CN104977417A (en) | Glycopeptide chip and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190530 Address after: 518116 Huitong Building, No. 10 Longgang Road, Pingnan Community, Longgang Street, Longgang District, Shenzhen City, Guangdong Province, 805 Applicant after: Shenzhen Bogang Biotechnology Co.,Ltd. Address before: Floor 1-2, Building No. 2, 500 Lane, Furong Hualu, Pudong New Area, Shanghai, 200120 Applicant before: SHANGHAI HAOGANG BIOTECHNOLOGY Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190322 |
|
| RJ01 | Rejection of invention patent application after publication |